MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 12.11.2025
Annovis Bio Operativer Cashflow 2011-2025 | ANVS
Operativer Cashflow Jährlich Annovis Bio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -40 M | -17.3 M | -9.13 M | -3.97 M | -477 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -477 K | -40 M | -14.2 M |
Operativer Cashflow Vierteljährlich Annovis Bio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -8.1 M | - | - | - | -7.03 M | - | - | - | -11.6 M | - | -13.7 M | -9.72 M | -3.02 M | - | -7.36 M | -5.62 M | -2.47 M | - | -3.2 M | -2.28 M | -970 K | - | -424 K | -379 K | -229 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -229 K | -13.7 M | -5.08 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-85.9 M | $ 4.71 | 0.86 % | $ 782 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 1.3 | - | $ 7.09 M |  China |
 |
Aclaris Therapeutics
ACRS
|
-20.1 M | $ 3.25 | - | $ 251 M |  USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 94.81 | - | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 0.28 | - | $ 609 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 14.09 | - | $ 928 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 220.42 | - | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.29 | -3.8 % | $ 7.92 B |  Australia |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectar Biosciences
CLRB
|
-32.4 M | $ 3.62 | - | $ 44.2 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
198 M | $ 87.99 | - | $ 9.08 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
240 M | $ 23.62 | - | $ 2.8 B | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-19 M | $ 1.45 | - | $ 2.14 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-396 M | $ 63.35 | - | $ 7.09 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Dynavax Technologies Corporation
DVAX
|
66.5 M | $ 10.8 | - | $ 1.4 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 25.27 | - | $ 1.22 B | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-1.79 M | $ 9.56 | 0.74 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
6.82 M | $ 16.7 | - | $ 428 M | USA |
 |
Exelixis
EXEL
|
700 M | $ 40.88 | - | $ 11.9 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
408 M | $ 564.28 | - | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.3 | - | $ 14.4 M | USA |
 |
AstraZeneca PLC
AZN
|
5.96 B | $ 89.83 | - | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.0 | - | $ 1.47 B | Britain |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-5.88 M | $ 1.05 | - | $ 977 K | Israel |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-831 M | $ 11.53 | -0.04 % | $ 746 M | USA |
 |
Biogen
BIIB
|
2.88 B | $ 174.1 | - | $ 25.3 B | USA |
 |
GeoVax Labs
GOVX
|
-25.2 M | $ 0.37 | - | $ 672 K | USA |